Halozyme ends trial of drug delivery system, shares slump
BY NATALIE GROVER Halozyme Therapeutics Inc halted a mid-stage trial testing an advanced version of its flagship drug delivery technology in patients with pancreatic cancer, sending its shares tumbling 32 ...